Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
AN2 Therapeutics, Inc. (ANTX)
USD4.67
-0.09 (-1.89%)
US NASDAQ Healthcare Biotechnology
Address
1800 El Camino Real 94027
Menlo Park, CA, US
Menlo Park, CA, US
CEO
Eric E. Easom
Website
an2therapeutics.com
IPO
2022-03-25
CIK 1880438 ISIN US0373261058
Description
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD4.67
-0.09 (-1.89%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
336.0K
Beta
-0.98
Float Shares
15.50M
Free Float %
56.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -9.53% | -6.97% | +41.86% | +302.83% | +277.88% | +274.56% | +261.86% | -21.65% | -72.27% | -72.27% | -72.27% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (8 ratings, all time)
Buy
Price Targets & DCF
Current price
4.67
Low
2.00
-57.2%
Consensus
7.75
+66.0%
Median
3.50
-25.1%
High
22.00
+371.1%
DCF (Unlevered)
0.59
-87.3%
DCF (Levered)
0.66
-85.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 7 |
12.43
+166.2%
|
Quality scores
Altman Z-Score
9.25
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+32.6% ★ Q1'26: +17.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.3% ★ Q1'26: +13.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
—
|
—
est: 33.20M (-100.0%)
|
72.70M
72.70M – 72.70M
+119.0% YoY
|
217.00M
217.00M – 217.00M
+198.5% YoY
|
389.90M
389.90M – 389.90M
+79.7% YoY
|
| EBITDA |
3.23M
|
-38.11M
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-51.32M
|
-38.11M
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-51.32M
est: -51.27M (-0.1%)
|
-35.17M
est: -33.84M (-3.9%)
|
-27.50M
-27.50M – -27.50M
+18.8% YoY
|
-24.17M
-24.17M – -24.17M
+12.1% YoY
|
-30.82M
-30.82M – -30.82M
-27.5% YoY
|
| SGA |
14.07M
|
13.34M
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1.72
est: -1.72 (+0.2%)
|
-1.16
est: -1.12 (-3.6%)
|
-0.91
-0.91 – -0.91
+18.8% YoY
|
-0.80
-0.80 – -0.80
+12.1% YoY
|
-1.02
-1.02 – -1.02
-27.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
37
Total invested
9.88M
Insider transactions (90d)
0
Beneficial owners (>5%)
24
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BML Investment Partners, L.P. | 4.25M | 14.20% | — | 4.25M | — | 4.25M | PN | Delaware | 2024-08-12 | ↗ |
| 2 | Eric Easom | 1.57M | 5.20% | 1.57M | — | 1.57M | — | IN | — | 2024-02-13 | ↗ |
| 3 | James N. Topper | 1.49M | 5.00% | — | 1.49M | — | 1.49M | IN | Delaware | 2024-04-10 | ↗ |
| 4 | Patrick J. Heron | 1.49M | 5.00% | — | 1.49M | — | 1.49M | IN | Delaware | 2024-04-10 | ↗ |
| 5 | Chen Yu | 1.29M | 6.60% | — | 1.29M | — | 1.29M | IN | Delaware | 2023-07-25 | ↗ |
| 6 | TCG Crossover Fund I, L.P. | 1.29M | 6.60% | — | 1.29M | — | 1.29M | PN | Delaware | 2023-07-25 | ↗ |
| 7 | Albert Cha | 1.15M | 3.80% | — | 1.15M | — | 1.15M | IN | Delaware | 2024-04-10 | ↗ |
| 8 | James Brush | 1.15M | 3.80% | — | 1.15M | — | 1.15M | IN | Delaware | 2024-04-10 | ↗ |
| 9 | FHMLSP, L.L.C. | 707.9K | 2.40% | — | 707.9K | — | 707.9K | OO | Delaware | 2024-04-10 | ↗ |
| 10 | FHMLSP, L.P. | 707.9K | 2.40% | — | 707.9K | — | 707.9K | PN | Delaware | 2024-04-10 | ↗ |
| 11 | Frazier Life Sciences Public Fund, L.P. | 707.9K | 2.40% | — | 707.9K | — | 707.9K | PN | Delaware | 2024-04-10 | ↗ |
| 12 | FHMLSP Overage, L.L.C. | 437.9K | 1.50% | — | 437.9K | — | 437.9K | OO | Delaware | 2024-04-10 | ↗ |
| 13 | FHMLSP Overage, L.P. | 437.9K | 1.50% | — | 437.9K | — | 437.9K | PN | Delaware | 2024-04-10 | ↗ |
| 14 | Frazier Life Sciences Public Overage Fund, L.P. | 437.9K | 1.50% | — | 437.9K | — | 437.9K | PN | Delaware | 2024-04-10 | ↗ |
| 15 | Daniel Estes | 282.2K | 0.90% | — | 282.2K | — | 282.2K | IN | Delaware | 2024-04-10 | ↗ |
| 16 | FHMLS XI, L.L.C. | 282.2K | 0.90% | — | 282.2K | — | 282.2K | OO | Delaware | 2024-04-10 | ↗ |
| 17 | FHMLS XI, L.P. | 282.2K | 0.90% | — | 282.2K | — | 282.2K | PN | Delaware | 2024-04-10 | ↗ |
| 18 | Frazier Life Sciences XI, L.P. | 282.2K | 0.90% | — | 282.2K | — | 282.2K | PN | Delaware | 2024-04-10 | ↗ |
| 19 | FHMLS X, L.L.C. | 60.9K | 0.20% | — | 60.9K | — | 60.9K | OO | Delaware | 2024-04-10 | ↗ |
| 20 | FHMLS X, L.P. | 60.9K | 0.20% | — | 60.9K | — | 60.9K | PN | Delaware | 2024-04-10 | ↗ |
| 21 | Frazier Life Sciences X, L.P. | 60.9K | 0.20% | — | 60.9K | — | 60.9K | PN | Delaware | 2024-04-10 | ↗ |
| 22 | Octagon Capital Advisors LP | — | 0.00% | — | — | — | — | IA, PN | Delaware | 2024-08-28 | ↗ |
| 23 | Octagon Investments Master Fund LP | — | 0.00% | — | — | — | — | PN, OO | Delaware | 2024-08-28 | ↗ |
| 24 | Ting Jia | — | 0.00% | — | — | — | — | HC, IN | Delaware | 2024-08-28 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q4
Investors holding
37
+2 vs prev Q
New positions
5
Closed positions
3
Increased
14
Reduced
8
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | ALMITAS CAPITAL LLC | 1.48M +50.8K (+3.6%) | 1.69M -127.8K (-7.0%) | 4.89% +0.168 pp | 0.37% -0.044 pp | USD1.35 -15.6% | 5 qtrs — |
| 2 | VANGUARD GROUP INC | 1.08M +— (+0.0%) | 1.23M -140.4K (-10.2%) | 3.57% +0.000 pp | 0.00% +0.000 pp | USD12.83 -91.1% | 16 qtrs — |
| 3 | PFIZER INC | 715.3K +— (+0.0%) | 815.4K -93.0K (-10.2%) | 2.36% +0.000 pp | 0.34% +0.137 pp | USD1.38 -17.4% | 5 qtrs — |
| 4 | STONEPINE CAPITAL MANAGEMENT, LLC | 627.7K +63.8K (+11.3%) | 715.5K -628.0 (-0.1%) | 2.07% +0.211 pp | 0.52% -0.060 pp | USD1.07 +6.5% | 5 qtrs — |
| 5 | PEAPOD LANE CAPITAL LLC | 593.4K +4.2K (+0.7%) | 676.5K -71.8K (-9.6%) | 1.96% +0.014 pp | 0.58% -0.094 pp | USD1.38 -17.4% | 5 qtrs — |
| 6 | BANK OF NOVA SCOTIA | 459.2K +— (+0.0%) | 523.5K -59.7K (-10.2%) | 1.52% +0.000 pp | 0.00% 0.000 pp | USD1.38 -17.4% | 5 qtrs — |
| 7 | LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | 431.8K -24.7K (-5.4%) | 492.2K -87.5K (-15.1%) | 1.43% -0.082 pp | 0.03% -0.004 pp | USD1.06 +7.5% | 3 qtrs — |
| 8 | BANK OF MONTREAL /CAN/ | 422.1K +— (+0.0%) | 481.2K -54.9K (-10.2%) | 1.39% +0.000 pp | 0.00% +0.000 pp | USD1.38 -17.4% | 5 qtrs — |
| 9 | BANK OF AMERICA CORP /DE/ | 385.3K +2.0 (+0.0%) | 439.3K -50.1K (-10.2%) | 1.27% +0.000 pp | 0.00% +0.000 pp | USD2.08 -45.2% | 15 qtrs — |
| 10 | RENAISSANCE TECHNOLOGIES LLC | 338.6K -47.0K (-12.2%) | 386.0K -103.7K (-21.2%) | 1.12% -0.155 pp | 0.00% +0.000 pp | USD1.17 -2.6% | 7 qtrs — |
| 11 | BLACKROCK, INC. | 323.3K +2.4K (+0.8%) | 368.6K -39.0K (-9.6%) | 1.07% +0.008 pp | 0.00% +0.000 pp | USD1.07 +6.5% | 6 qtrs — |
| 12 | TWO SIGMA ADVISERS, LP | 264.9K -3.0K (-1.1%) | 302.0K -38.2K (-11.2%) | 0.87% -0.010 pp | 0.00% 0.000 pp | USD1.55 -26.5% | 7 qtrs — |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 251.9K +2.5K (+1.0%) | 287.2K -29.5K (-9.3%) | 0.83% +0.008 pp | 0.00% +0.000 pp | USD11.65 -90.2% | 15 qtrs — |
| 14 | MORGAN STANLEY | 229.8K +39.0K (+20.4%) | 261.9K +19.7K (+8.1%) | 0.76% +0.129 pp | 0.00% +0.000 pp | USD1.09 +4.6% | 16 qtrs — |
| 15 | TWO SIGMA INVESTMENTS, LP | 178.5K -44.8K (-20.1%) | 203.5K -80.1K (-28.2%) | 0.59% -0.148 pp | 0.00% 0.000 pp | USD2.78 -59.0% | 9 qtrs — |
| 16 | WOODLINE PARTNERS LP | 146.0K +146.0K (+100.0%) | 166.4K +166.4K (+100.0%) | 0.48% +0.482 pp | 0.00% +0.001 pp | USD1.14 +0.0% | 1 qtrs NEW |
| 17 | CITADEL ADVISORS LLC | 115.5K +92.5K (+402.0%) | 131.7K +102.5K (+350.6%) | 0.38% +0.306 pp | 0.00% +0.000 pp | USD1.14 +0.0% | 16 qtrs — |
| 18 | MILLENNIUM MANAGEMENT LLC | 95.7K +95.7K (+100.0%) | 109.1K +109.1K (+100.0%) | 0.32% +0.316 pp | 0.00% +0.000 pp | USD1.14 +0.0% | 1 qtrs NEW |
| 19 | STATE STREET CORP | 87.0K +— (+0.0%) | 99.2K -11.3K (-10.2%) | 0.29% +0.000 pp | 0.00% +0.000 pp | USD8.43 -86.5% | 15 qtrs — |
| 20 | RANGELEY CAPITAL, LLC | 65.0K +— (+0.0%) | 74.1K -8.5K (-10.2%) | 0.21% +0.000 pp | 0.06% -0.010 pp | USD1.29 -11.6% | 4 qtrs — |
| 21 | SQUAREPOINT OPS LLC | 61.6K -2.7K (-4.1%) | 70.2K -11.4K (-13.9%) | 0.20% -0.009 pp | 0.00% +0.000 pp | USD1.24 -8.1% | 8 qtrs — |
| 22 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 59.9K +— (+0.0%) | 68.3K -7.8K (-10.2%) | 0.20% +0.000 pp | 0.00% 0.000 pp | USD3.01 -62.1% | 12 qtrs — |
| 23 | UBS GROUP AG | 56.7K -26.0 (0.0%) | 64.6K -7.4K (-10.3%) | 0.19% 0.000 pp | 0.00% +0.000 pp | USD1.38 -17.4% | 16 qtrs — |
| 24 | NORTHERN TRUST CORP | 43.2K +— (+0.0%) | 49.2K -5.6K (-10.2%) | 0.14% +0.000 pp | 0.00% +0.000 pp | USD13.13 -91.3% | 15 qtrs — |
| 25 | CAPTRUST FINANCIAL ADVISORS | 40.0K +— (+0.0%) | 45.6K -5.2K (-10.2%) | 0.13% +0.000 pp | 0.00% +0.000 pp | USD4.81 -76.3% | 10 qtrs — |
| 26 | PRIVATE ADVISOR GROUP, LLC | 22.5K +— (+0.0%) | 25.7K -2.9K (-10.2%) | 0.07% +0.000 pp | 0.00% +0.000 pp | USD3.76 -69.7% | 8 qtrs — |
| 27 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 22.2K +22.2K (+100.0%) | 25.4K +25.4K (+100.0%) | 0.07% +0.074 pp | 0.00% +0.000 pp | USD1.14 +0.0% | 3 qtrs — |
| 28 | JANE STREET GROUP, LLC | 17.9K +17.9K (+100.0%) | 20.4K +20.4K (+100.0%) | 0.06% +0.059 pp | 0.00% +0.000 pp | USD1.14 +0.0% | 1 qtrs NEW |
| 29 | SCHONFELD STRATEGIC ADVISORS LLC | 14.3K +— (+0.0%) | 16.3K -1.9K (-10.2%) | 0.05% +0.000 pp | 0.00% +0.000 pp | USD1.42 -19.7% | 7 qtrs — |
| 30 | FEDERATED HERMES, INC. | 11.5K -403.0 (-3.4%) | 13.1K -2.0K (-13.3%) | 0.04% -0.001 pp | 0.00% +0.000 pp | USD1.66 -31.3% | 10 qtrs — |
| 31 | VALEO FINANCIAL ADVISORS, LLC | 10.4K +10.4K (+100.0%) | 11.9K +11.9K (+100.0%) | 0.03% +0.035 pp | 0.00% +0.000 pp | USD1.14 +0.0% | 1 qtrs NEW |
| 32 | QUBE RESEARCH & TECHNOLOGIES LTD | 10.2K +— (+0.0%) | 11.6K -1.3K (-10.2%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD1.38 -17.4% | 11 qtrs — |
| 33 | TOWER RESEARCH CAPITAL LLC (TRC) | 2.0K -88.0 (-4.1%) | 2.3K -377.0 (-13.9%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD1.52 -25.0% | 16 qtrs — |
| 34 | FMR LLC | 1.2K +200.0 (+20.0%) | 1.4K +98.0 (+7.7%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD1.25 -8.8% | 2 qtrs — |
| 35 | BNP PARIBAS ARBITRAGE, SNC | 303.00 +— (+0.0%) | 345.00 -40.0 (-10.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.38 -17.4% | 5 qtrs — |
| 36 | ADVISOR GROUP HOLDINGS, INC. | 300.00 +— (+0.0%) | 342.00 -42.0 (-10.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD12.00 -90.5% | 15 qtrs — |
| 37 | SBI SECURITIES CO., LTD. | 200.00 +— (+0.0%) | 228.00 -26.0 (-10.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.38 -17.4% | 5 qtrs — |
| 38 | XTX TOPCO LTD | — -18.5K (-100.0%) | — -23.5K (-100.0%) | 0.00% -0.061 pp | 0.00% -0.001 pp | USD— | 8 qtrs SOLD |
| 39 | HIGHLINE WEALTH PARTNERS LLC | — -5.0K (-100.0%) | — -6.4K (-100.0%) | 0.00% -0.017 pp | 0.00% -0.002 pp | USD— | 3 qtrs SOLD |
| 40 | ACT ADVISORS, LLC. | — -13.2K (-100.0%) | — -16.8K (-100.0%) | 0.00% -0.044 pp | 0.00% -0.007 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 39 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.03% | 399.8K | 0.60% |
| 2 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.02% | 170.8K | 0.20% |
| 3 | iShares Russell 2000 Value ETF IWN | 0.01% | 869.6K | 0.24% |
| 4 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.00% | 120.9K | 0.30% |
| 5 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.00% | 12.2K | 0.25% |
| 6 | Global X - Russell 2000 ETF RSSL | 0.00% | 55.7K | 0.08% |
| 7 | iShares Russell 2000 BuyWrite ETF IWMW | 0.00% | 1.9K | 0.39% |
| 8 | iShares Russell 2000 ETF IWM | 0.00% | 2.77M | 0.19% |
| 9 | iShares U.S. Small Cap Index ETF (CAD-Hedged) XSU.TO | 0.00% | 18.1K | 0.36% |
| 10 | ProShares - Ultra Russell2000 UWM | 0.00% | 4.7K | 1.07% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
3
Sells
0
Shares acquired
8.7K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+8,742
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-10 | Martin Patricia A. | Director | A-Award | A | Common Stock | 1,192 | 0.00 | — | 18,097 | D | ↗ |
| 2026-04-10 | Marks Gilbert Lynn | Director | A-Award | A | Common Stock | 3,775 | 0.00 | — | 79,084 | D | ↗ |
| 2026-04-10 | Aziz Kabeer | Director | A-Award | A | Common Stock | 3,775 | 0.00 | — | 56,254 | D | ↗ |
| 2026-03-19 | Zakrzewski Joseph S | Director | A-Award | A | Stock Option (right to buy) | 23,742 | 3.91 | 92.8K | 23,742 | D | ↗ |
| 2026-03-19 | Wong Stephanie | Director | D-Return | D | Stock Option (right to buy) | 24,999 | 6.60 | 164.9K | 0 | D | ↗ |
| 2026-03-19 | Spigelman Melvin K | Director | A-Award | A | Stock Option (right to buy) | 23,742 | 3.91 | 92.8K | 23,742 | D | ↗ |
| 2026-03-19 | Readnour Robin Shane | Director | A-Award | A | Stock Option (right to buy) | 23,742 | 3.91 | 92.8K | 23,742 | D | ↗ |
| 2026-03-19 | Martin Patricia A. | Director | A-Award | A | Stock Option (right to buy) | 23,742 | 3.91 | 92.8K | 23,742 | D | ↗ |
| 2026-03-19 | Marks Gilbert Lynn | Director | A-Award | A | Stock Option (right to buy) | 10,665 | 3.91 | 41.7K | 10,665 | D | ↗ |
| 2026-03-19 | FitzPatrick Margaret M | Director | D-Return | D | Stock Option (right to buy) | 11,463 | 18.24 | 209.1K | 0 | D | ↗ |
| 2026-03-19 | Eizen Joshua M | Officer | D-Return | D | Stock Option (right to buy) | 92,000 | 17.88 | 1.64M | 0 | D | ↗ |
| 2026-03-19 | Easom Eric | Director / Officer | A-Award | A | Stock Option (right to buy) | 267,650 | 3.91 | 1.05M | 267,650 | D | ↗ |
| 2026-03-19 | Day Lucy | Officer | D-Return | D | Stock Option (right to buy) | 66,000 | 17.28 | 1.14M | 0 | D | ↗ |
| 2026-03-19 | Chanda Sanjay | Officer | A-Award | A | Stock Option (right to buy) | 57,950 | 3.91 | 226.6K | 57,950 | D | ↗ |
| 2026-03-19 | Aziz Kabeer | Director | D-Return | D | Stock Option (right to buy) | 23,742 | 5.91 | 140.3K | 0 | D | ↗ |
| 2026-03-03 | Williams Sarah Joanne | Officer | S-Sale | D | Common Stock | 327 | 1.06 | 346.62 | 66,848 | D | ↗ |
| 2026-02-20 | Zakrzewski Joseph S | Director | A-Award | A | Stock Option (Right to Buy) | 20,400 | 1.04 | 21.2K | 20,400 | D | ↗ |
| 2026-02-20 | Wong Stephanie | Director | A-Award | A | Stock Option (Right to Buy) | 20,400 | 1.04 | 21.2K | 20,400 | D | ↗ |
| 2026-02-20 | Williams Sarah Joanne | Officer | A-Award | A | Common Stock | 48,375 | 0.00 | — | 67,175 | D | ↗ |
| 2026-02-20 | Spigelman Melvin K | Director | A-Award | A | Stock Option (Right to Buy) | 20,400 | 1.04 | 21.2K | 20,400 | D | ↗ |
| 2026-02-20 | Readnour Robin Shane | Director | A-Award | A | Stock Option (Right to Buy) | 20,400 | 1.04 | 21.2K | 20,400 | D | ↗ |
| 2026-02-20 | Martin Patricia A. | Director | A-Award | A | Stock Option (Right to Buy) | 20,400 | 1.04 | 21.2K | 20,400 | D | ↗ |
| 2026-02-20 | Marks Gilbert Lynn | Director | A-Award | A | Stock Option (Right to Buy) | 20,400 | 1.04 | 21.2K | 20,400 | D | ↗ |
| 2026-02-20 | FitzPatrick Margaret M | Director | A-Award | A | Stock Option (Right to Buy) | 20,400 | 1.04 | 21.2K | 20,400 | D | ↗ |
| 2026-02-20 | Eizen Joshua M | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 1.04 | 104.0K | 100,000 | D | ↗ |
| 2026-02-20 | Easom Eric | Director / Officer | A-Award | A | Common Stock | 112,250 | 0.00 | — | 368,630 | D | ↗ |
| 2026-02-20 | Day Lucy | Officer | A-Award | D | Stock Option (right to buy) | 77,000 | 1.04 | 80.1K | 77,000 | D | ↗ |
| 2026-02-20 | Chanda Sanjay | Officer | A-Award | A | Stock Option (right to buy) | 77,000 | 1.04 | 80.1K | 77,000 | D | ↗ |
| 2026-02-20 | Aziz Kabeer | Director | A-Award | A | Stock Option (Right to Buy) | 20,400 | 1.04 | 21.2K | 20,400 | D | ↗ |
| 2026-01-26 | Williams Sarah Joanne | Officer | — | — | Stock Option (right to buy) | 23,700 | 2.07 | 49.1K | 0 | D | ↗ |
| 2026-01-12 | Martin Patricia A. | Director | A-Award | A | Common Stock | 3,650 | 0.00 | — | 16,905 | D | ↗ |
| 2026-01-12 | Marks Gilbert Lynn | Director | A-Award | A | Common Stock | 11,560 | 0.00 | — | 75,309 | D | ↗ |
| 2026-01-12 | Aziz Kabeer | Director | A-Award | A | Common Stock | 11,560 | 0.00 | — | 52,479 | D | ↗ |
| 2026-01-06 | Prior Stephen David | Officer | S-Sale | D | Common Stock | 2,858 | 1.01 | 2.9K | 59,086 | D | ↗ |
| 2026-01-06 | Eizen Joshua M | Officer | S-Sale | D | Common Stock | 6,931 | 1.01 | 7.0K | 152,499 | D | ↗ |
| 2026-01-06 | Day Lucy | Officer | S-Sale | D | Common Stock | 5,512 | 1.01 | 5.6K | 75,363 | D | ↗ |
| 2026-01-06 | Chanda Sanjay | Officer | S-Sale | D | Common Stock | 5,956 | 1.01 | 6.0K | 75,823 | D | ↗ |
| 2026-01-05 | Prior Stephen David | Officer | S-Sale | D | Common Stock | 3,604 | 1.00 | 3.6K | 61,944 | D | ↗ |
| 2026-01-05 | Eizen Joshua M | Officer | S-Sale | D | Common Stock | 17,923 | 1.00 | 17.9K | 159,430 | D | ↗ |
| 2026-01-05 | Day Lucy | Officer | S-Sale | D | Common Stock | 3,295 | 1.00 | 3.3K | 80,875 | D | ↗ |
| 2026-01-05 | Chanda Sanjay | Officer | S-Sale | D | Common Stock | 3,295 | 1.00 | 3.3K | 81,779 | D | ↗ |
| 2025-11-04 | Prior Stephen David | Officer | S-Sale | D | Common Stock | 765 | 1.14 | 872.10 | 65,548 | D | ↗ |
| 2025-11-04 | Eizen Joshua M | Officer | S-Sale | D | Common Stock | 2,819 | 1.14 | 3.2K | 177,353 | D | ↗ |
| 2025-10-10 | Martin Patricia A. | Director | A-Award | A | Common Stock | 3,274 | 0.00 | — | 13,255 | D | ↗ |
| 2025-10-10 | Marks Gilbert Lynn | Director | A-Award | A | Common Stock | 10,367 | 0.00 | — | 63,749 | D | ↗ |
| 2025-10-10 | Aziz Kabeer | Director | A-Award | A | Common Stock | 10,367 | 0.00 | — | 40,919 | D | ↗ |
| 2025-07-10 | Martin Patricia A. | Director | A-Award | A | Common Stock | 3,750 | 0.00 | — | 9,981 | D | ↗ |
| 2025-07-10 | Marks Gilbert Lynn | Director | A-Award | A | Common Stock | 11,875 | 0.00 | — | 53,382 | D | ↗ |
| 2025-07-10 | Aziz Kabeer | Director | A-Award | A | Common Stock | 11,875 | 0.00 | — | 30,552 | D | ↗ |
| 2025-06-02 | Easom Eric | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 1.07 | 10.7K | 256,380 | D | ↗ |
| 2025-05-30 | Leonard Braden Michael | 10% Owner | S-Sale | D | Common Stock | 425,000 | 1.01 | 429.3K | 3,224,432 | I | ↗ |
| 2025-05-28 | Leonard Braden Michael | 10% Owner | S-Sale | D | Common Stock | 200,000 | 1.09 | 218.0K | 3,017,432 | I | ↗ |
| 2025-05-28 | FitzPatrick Margaret M | Director | P-Purchase | A | Common Stock | 8,610 | 1.18 | 10.1K | 8,610 | D | ↗ |
| 2025-05-22 | Zakrzewski Joseph S | Director | A-Award | A | Stock Option (Right to Buy) | 19,111 | 1.19 | 22.7K | 19,111 | D | ↗ |
| 2025-05-22 | Wong Stephanie | Director | A-Award | A | Stock Option (Right to Buy) | 19,111 | 1.19 | 22.7K | 19,111 | D | ↗ |
| 2025-05-22 | Spigelman Melvin K | Director | A-Award | A | Stock Option (Right to Buy) | 19,111 | 1.19 | 22.7K | 19,111 | D | ↗ |
| 2025-05-22 | Readnour Robin Shane | Director | A-Award | A | Stock Option (Right to Buy) | 19,111 | 1.19 | 22.7K | 19,111 | D | ↗ |
| 2025-05-22 | Martin Patricia A. | Director | A-Award | A | Stock Option (Right to Buy) | 19,111 | 1.19 | 22.7K | 19,111 | D | ↗ |
| 2025-05-22 | Marks Gilbert Lynn | Director | A-Award | A | Stock Option (Right to Buy) | 19,111 | 1.19 | 22.7K | 19,111 | D | ↗ |
| 2025-05-22 | FitzPatrick Margaret M | Director | A-Award | A | Stock Option (Right to Buy) | 19,111 | 1.19 | 22.7K | 19,111 | D | ↗ |
| 2025-05-22 | Aziz Kabeer | Director | A-Award | A | Stock Optin (Right to Buy) | 19,111 | 1.19 | 22.7K | 19,111 | D | ↗ |
| 2025-04-10 | Zakrzewski Joseph S | Director | A-Award | A | Common Stock | 10,523 | 0.00 | — | 145,538 | D | ↗ |
| 2025-04-10 | Marks Gilbert Lynn | Director | A-Award | A | Common Stock | 9,705 | 0.00 | — | 41,507 | D | ↗ |
| 2025-04-10 | Aziz Kabeer | Director | A-Award | A | Common Stock | 9,705 | 0.00 | — | 18,677 | D | ↗ |
| 2025-02-26 | Prior Stephen David | Officer | A-Award | A | Stock Option (right to buy) | 56,000 | 1.13 | 63.3K | 56,000 | D | ↗ |
| 2025-02-26 | Eizen Joshua M | Officer | A-Award | A | Common Stock | 58,500 | 0.00 | — | 175,172 | D | ↗ |
| 2025-02-26 | Easom Eric | Director / Officer | A-Award | A | Common Stock | 145,250 | 0.00 | — | 246,380 | D | ↗ |
| 2025-02-26 | Day Lucy | Officer | A-Award | A | Common Stock | 46,500 | 0.00 | — | 79,170 | D | ↗ |
| 2025-02-26 | Chanda Sanjay | Officer | A-Award | A | Common Stock | 50,250 | 0.00 | — | 80,074 | D | ↗ |
| 2025-01-03 | Prior Stephen David | Officer | S-Sale | D | Common Stock | 2,029 | 1.34 | 2.7K | 33,313 | D | ↗ |
| 2025-01-03 | Eizen Joshua M | Officer | S-Sale | D | Common Stock | 9,663 | 1.34 | 13.0K | 116,672 | D | ↗ |
| 2025-01-03 | Day Lucy | Officer | S-Sale | D | Common Stock | 2,957 | 1.34 | 4.0K | 32,670 | D | ↗ |
| 2025-01-03 | Chanda Sanjay | Officer | S-Sale | D | Common Stock | 2,957 | 1.34 | 4.0K | 29,824 | D | ↗ |
| 2024-12-19 | Zakrzewski Joseph S | Director | A-Award | A | Common Stock | 9,816 | 0.00 | — | 135,015 | D | ↗ |
| 2024-12-19 | Readnour Robin Shane | Director | A-Award | A | Common Stock | 9,077 | 0.00 | — | 9,077 | D | ↗ |
| 2024-12-19 | Martin Patricia A. | Director | A-Award | A | Common Stock | 3,166 | 0.00 | — | 3,166 | D | ↗ |
| 2024-12-19 | Marks Gilbert Lynn | Director | A-Award | A | Common Stock | 8,972 | 0.00 | — | 31,802 | D | ↗ |
| 2024-12-19 | Aziz Kabeer | Director | A-Award | A | Common Stock | 8,972 | 0.00 | — | 8,972 | D | ↗ |
| 2024-12-10 | Readnour Robin Shane | Director | P-Purchase | A | Common Stock | 5,000 | 1.49 | 7.5K | 652,573 | I | ↗ |
| 2024-12-09 | Readnour Robin Shane | Director | P-Purchase | A | Common Stock | 18,483 | 1.43 | 26.4K | 647,573 | I | ↗ |
| 2024-12-06 | Readnour Robin Shane | Director | P-Purchase | A | Common Stock | 6,517 | 1.45 | 9.4K | 629,090 | I | ↗ |
| 2024-11-27 | Zakrzewski Joseph S | Director | P-Purchase | A | Common Stock | 2,000 | 1.40 | 2.8K | 125,199 | D | ↗ |
| 2024-11-27 | Readnour Robin Shane | Director | P-Purchase | A | Common Stock | 25,000 | 1.42 | 35.4K | 552,288 | I | ↗ |
| 2024-11-26 | Readnour Robin Shane | Director | P-Purchase | A | Common Stock | 12,500 | 1.39 | 17.4K | 527,288 | I | ↗ |
| 2024-11-20 | Readnour Robin Shane | Director | P-Purchase | A | Common Stock | 25,000 | 1.16 | 29.0K | 585,073 | I | ↗ |
| 2024-11-19 | Zakrzewski Joseph S | Director | P-Purchase | A | Common Stock | 5,000 | 1.01 | 5.1K | 123,199 | D | ↗ |
| 2024-11-19 | Readnour Robin Shane | Director | P-Purchase | A | Common Stock | 75,000 | 1.03 | 77.5K | 560,073 | I | ↗ |
| 2024-11-18 | Zakrzewski Joseph S | Director | P-Purchase | A | Common Stock | 20,000 | 1.00 | 20.0K | 118,199 | D | ↗ |
| 2024-11-18 | Easom Eric | Director / Officer | P-Purchase | A | Common Stock | 50,000 | 1.00 | 50.0K | 1,065,766 | I | ↗ |
| 2024-11-04 | Prior Stephen David | Officer | — | — | Stock Option (right to buy) | 35,000 | 0.00 | — | 0 | D | ↗ |
| 2024-11-04 | Eizen Joshua M | Officer | A-Award | A | Stock Option (right to buy) | 63,000 | 1.08 | 68.0K | 63,000 | D | ↗ |
| 2024-08-14 | Leonard Braden Michael | 10% Owner | P-Purchase | A | Common Stock | 1,500,000 | 1.04 | 1.56M | 5,749,432 | — | ↗ |
| 2024-08-09 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | S-Sale | D | Common Stock | 3,410,335 | 1.08 | 3.68M | 1,725,348 | — | ↗ |
| 2024-08-09 | Leonard Braden Michael | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 4,249,432 | — | ↗ |
| 2024-07-10 | Eizen Joshua M | Officer | A-Award | A | Common Stock | 60,000 | 0.00 | — | 94,833 | — | ↗ |
| 2024-06-19 | Zakrzewski Joseph S | Director | A-Award | A | Stock Option (Right to Buy) | 64,503 | 2.00 | 129.0K | 64,503 | — | ↗ |
| 2024-06-19 | Wong Stephanie | Director | A-Award | A | Stock Option (Right to Buy) | 64,503 | 2.00 | 129.0K | 64,503 | — | ↗ |
| 2024-06-19 | Spigelman Melvin K | Director | A-Award | A | Stock Option (Right to Buy) | 64,503 | 2.00 | 129.0K | 64,503 | — | ↗ |
| 2024-06-19 | Readnour Robin Shane | Director | A-Award | A | Stock Option (Right to Buy) | 64,503 | 2.00 | 129.0K | 64,503 | — | ↗ |
| 2024-06-19 | Martin Patricia A. | Director | A-Award | A | Stock Option (Right to Buy) | 64,503 | 2.00 | 129.0K | 64,503 | — | ↗ |
| 2024-06-19 | Marks Gilbert Lynn | Director | A-Award | A | Stock Option (Right to Buy) | 64,503 | 2.00 | 129.0K | 64,503 | — | ↗ |
| 2024-06-19 | FitzPatrick Margaret M | Director | A-Award | A | Stock Option (Right to Buy) | 64,503 | 2.00 | 129.0K | 64,503 | — | ↗ |
| 2024-06-19 | Aziz Kabeer | Director | A-Award | A | Stock Option (Right to Buy) | 64,503 | 2.00 | 129.0K | 64,503 | — | ↗ |
| 2024-03-15 | Krause Kevin Michael | Officer | A-Award | A | Stock Option (right to buy) | 60,000 | 3.00 | 180.0K | 60,000 | — | ↗ |
| 2024-03-15 | Eizen Joshua M | Officer | A-Award | A | Common Stock | 30,000 | 0.00 | — | 32,447 | — | ↗ |
| 2024-03-15 | Eckburg Paul | Officer | A-Award | A | Common Stock | 30,000 | 0.00 | — | 51,416 | — | ↗ |
| 2024-03-15 | Easom Eric | Director / Officer | A-Award | A | Stock Option (right to buy) | 198,000 | 3.00 | 594.0K | 198,000 | — | ↗ |
| 2024-03-15 | Day Lucy | Officer | A-Award | A | Stock Option (right to buy) | 55,000 | 3.00 | 165.0K | 55,000 | — | ↗ |
| 2024-03-15 | Chanda Sanjay | Officer | A-Award | A | Stock Option (right to buy) | 55,000 | 3.00 | 165.0K | 55,000 | — | ↗ |
| 2024-01-18 | Zakrzewski Joseph S | Director | S-Sale | D | Common Stock | 100,000 | 19.11 | 1.91M | 405,880 | — | ↗ |
| 2024-01-16 | Aziz Kabeer | Director | S-Sale | D | Common Stock | 15,907 | 19.65 | 312.6K | 377,542 | — | ↗ |
| 2024-01-16 | Adjuvant Global Health Technology Fund, L.P. | 10% Owner | S-Sale | D | Common Stock | 15,907 | 19.65 | 312.6K | 377,542 | — | ↗ |
| 2024-01-12 | Readnour Robin Shane | Director | S-Sale | D | Common Stock | 719 | 21.91 | 15.8K | 485,073 | — | ↗ |
| 2024-01-10 | Readnour Robin Shane | Director | S-Sale | D | Common Stock | 1,800 | 21.92 | 39.5K | 485,792 | — | ↗ |
| 2024-01-09 | Krause Kevin Michael | Officer | M-Exempt | D | Stock Option (right to buy) | 2,417 | 0.42 | 1.0K | 49,868 | — | ↗ |
| 2024-01-02 | Krause Kevin Michael | Officer | S-Sale | D | Common Stock | 2,583 | 20.12 | 52.0K | 1,914 | — | ↗ |
| 2024-01-02 | Easom Eric | Director / Officer | S-Sale | D | Common Stock | 2,777 | 20.09 | 55.8K | 2,130 | — | ↗ |
| 2023-11-14 | Aziz Kabeer | Director / 10% Owner | S-Sale | D | Common Stock | 1,522 | 16.15 | 24.6K | 2,080,051 | — | ↗ |
| 2023-11-14 | Adjuvant Global Health Technology Fund, L.P. | 10% Owner | S-Sale | D | Common Stock | 1,522 | 16.15 | 24.6K | 2,080,051 | — | ↗ |
| 2023-10-02 | Aziz Kabeer | Director / 10% Owner | S-Sale | D | Common Stock | 4,770 | 16.07 | 76.7K | 2,081,573 | — | ↗ |
| 2023-10-02 | Adjuvant Global Health Technology Fund, L.P. | 10% Owner | S-Sale | D | Common Stock | 4,770 | 16.07 | 76.7K | 2,081,573 | — | ↗ |
| 2023-09-29 | Aziz Kabeer | Director / 10% Owner | S-Sale | D | Common Stock | 15,764 | 16.28 | 256.6K | 394,639 | — | ↗ |
| 2023-09-29 | Adjuvant Global Health Technology Fund, L.P. | 10% Owner | S-Sale | D | Common Stock | 15,764 | 16.28 | 256.6K | 394,639 | — | ↗ |
| 2023-09-28 | Aziz Kabeer | Director / 10% Owner | S-Sale | D | Common Stock | 1,356 | 16.11 | 21.8K | 410,403 | — | ↗ |
| 2023-09-28 | Adjuvant Global Health Technology Fund, L.P. | 10% Owner | S-Sale | D | Common Stock | 7,160 | 16.11 | 115.3K | 2,169,680 | — | ↗ |
| 2023-09-27 | Aziz Kabeer | Director / 10% Owner | S-Sale | D | Common Stock | 707 | 16.07 | 11.4K | 2,176,840 | — | ↗ |
| 2023-09-27 | Adjuvant Global Health Technology Fund, L.P. | 10% Owner | S-Sale | D | Common Stock | 707 | 16.07 | 11.4K | 2,176,840 | — | ↗ |
| 2023-09-13 | Aziz Kabeer | Director / 10% Owner | S-Sale | D | Common Stock | 64 | 16.00 | 1.0K | 411,893 | — | ↗ |
| 2023-09-13 | Adjuvant Global Health Technology Fund, L.P. | 10% Owner | S-Sale | D | Common Stock | 336 | 16.00 | 5.4K | 2,177,547 | — | ↗ |
| 2023-09-07 | Aziz Kabeer | Director / 10% Owner | S-Sale | D | Common Stock | 2,841 | 16.05 | 45.6K | 2,177,883 | — | ↗ |
| 2023-09-07 | Adjuvant Global Health Technology Fund, L.P. | 10% Owner | S-Sale | D | Common Stock | 2,841 | 16.05 | 45.6K | 2,177,883 | — | ↗ |
| 2023-09-06 | Aziz Kabeer | Director / 10% Owner | S-Sale | D | Common Stock | 598 | 16.02 | 9.6K | 412,494 | — | ↗ |
| 2023-09-06 | Adjuvant Global Health Technology Fund, L.P. | 10% Owner | S-Sale | D | Common Stock | 3,164 | 16.02 | 50.7K | 2,180,724 | — | ↗ |
| 2023-08-23 | Aziz Kabeer | Director / 10% Owner | S-Sale | D | Common Stock | 336 | 16.00 | 5.4K | 2,183,888 | — | ↗ |
| 2023-08-23 | Adjuvant Global Health Technology Fund, L.P. | 10% Owner | S-Sale | D | Common Stock | 64 | 16.00 | 1.0K | 413,092 | — | ↗ |
| 2023-08-18 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | P-Purchase | A | Common Stock | 1,777,778 | 9.00 | 16.00M | 5,135,683 | — | ↗ |
| 2023-06-07 | Zakrzewski Joseph S | Director | A-Award | A | Stock Option (right to buy) | 23,742 | 5.91 | 140.3K | 23,742 | — | ↗ |
| 2023-06-07 | Wong Stephanie | Director | A-Award | A | Stock Option (right to buy) | 23,742 | 5.91 | 140.3K | 23,742 | — | ↗ |
| 2023-06-07 | Spigelman Melvin K | Director | A-Award | A | Stock Option (right to buy) | 23,742 | 5.91 | 140.3K | 23,742 | — | ↗ |
| 2023-06-07 | Readnour Robin Shane | Director | A-Award | A | Stock Option (right to buy) | 23,742 | 5.91 | 140.3K | 23,742 | — | ↗ |
| 2023-06-07 | Martin Patricia A. | Director | A-Award | A | Stock Option (right to buy) | 23,742 | 5.91 | 140.3K | 23,742 | — | ↗ |
| 2023-06-07 | Marks Gilbert Lynn | Director | A-Award | A | Stock Option (right to buy) | 23,742 | 5.91 | 140.3K | 23,742 | — | ↗ |
| 2023-06-07 | FitzPatrick Margaret M | Director | A-Award | A | Stock Option (right to buy) | 23,742 | 5.91 | 140.3K | 23,742 | — | ↗ |
| 2023-06-07 | Aziz Kabeer | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 23,742 | 5.91 | 140.3K | 23,742 | — | ↗ |
| 2023-05-15 | Easom Eric | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 5.38 | 53.8K | 1,015,766 | — | ↗ |
| 2023-02-23 | Easom Eric | Director / Officer | A-Award | A | Stock Option (right to buy) | 267,650 | 11.99 | 3.21M | 267,650 | — | ↗ |
| 2023-02-15 | Nazak Michael Adrian | Officer | A-Award | A | Stock Option (right to buy) | 16,600 | 14.29 | 237.2K | 16,600 | — | ↗ |
| 2023-02-15 | Krause Kevin Michael | Officer | A-Award | A | Stock Option (right to buy) | 62,200 | 14.29 | 888.8K | 62,200 | — | ↗ |
| 2023-02-15 | Eizen Joshua M | Officer | A-Award | A | Stock Option (right to buy) | 50,150 | 14.29 | 716.6K | 50,150 | — | ↗ |
| 2023-02-15 | Eckburg Paul | Officer | A-Award | A | Stock Option (right to buy) | 70,950 | 14.29 | 1.01M | 70,950 | — | ↗ |
| 2023-02-15 | Day Lucy | Officer | A-Award | A | Stock Option (right to buy) | 82,300 | 14.29 | 1.18M | 82,300 | — | ↗ |
| 2023-02-15 | Chanda Sanjay | Officer | A-Award | A | Stock Option (right to buy) | 57,950 | 14.29 | 828.1K | 57,950 | — | ↗ |
| 2022-11-14 | Easom Eric | Officer | S-Sale | D | Common Stock | 23 | 15.04 | 345.92 | 4,907 | — | ↗ |
| 2022-11-10 | Easom Eric | Officer | S-Sale | D | Common Stock | 4,413 | 15.32 | 67.6K | 4,930 | — | ↗ |
| 2022-11-09 | Easom Eric | Officer | S-Sale | D | Common Stock | 10,111 | 15.61 | 157.8K | 4,907 | — | ↗ |
| 2022-11-08 | Easom Eric | Officer | S-Sale | D | Common Stock | 5,800 | 15.41 | 89.4K | 16,273 | — | ↗ |
| 2022-11-07 | Easom Eric | Officer | S-Sale | D | Common Stock | 2,036 | 16.72 | 34.0K | 4,907 | — | ↗ |
| 2022-11-04 | Easom Eric | Officer | S-Sale | D | Common Stock | 8,828 | 15.80 | 139.5K | 17,110 | — | ↗ |
| 2022-11-03 | Easom Eric | Officer | S-Sale | D | Common Stock | 3,083 | 16.02 | 49.4K | 25,938 | — | ↗ |
| 2022-11-02 | Easom Eric | Officer | S-Sale | D | Common Stock | 1,544 | 15.07 | 23.3K | 4,907 | — | ↗ |
| 2022-10-31 | Easom Eric | Officer | S-Sale | D | Common Stock | 2,688 | 15.39 | 41.4K | 6,451 | — | ↗ |
| 2022-10-28 | Easom Eric | Officer | S-Sale | D | Common Stock | 1,683 | 15.09 | 25.4K | 4,907 | — | ↗ |
| 2022-10-27 | Easom Eric | Officer | S-Sale | D | Common Stock | 924 | 15.36 | 14.2K | 6,590 | — | ↗ |
| 2022-10-26 | Easom Eric | Officer | S-Sale | D | Common Stock | 1,678 | 15.10 | 25.3K | 4,907 | — | ↗ |
| 2022-10-25 | Easom Eric | Officer | S-Sale | D | Common Stock | 534 | 16.20 | 8.7K | 6,585 | — | ↗ |
| 2022-10-24 | Easom Eric | Officer | S-Sale | D | Common Stock | 2,866 | 16.17 | 46.3K | 11,391 | — | ↗ |
| 2022-10-21 | Easom Eric | Officer | S-Sale | D | Common Stock | 11,601 | 16.29 | 189.0K | 7,257 | — | ↗ |
| 2022-10-20 | Easom Eric | Officer | S-Sale | D | Common Stock | 7,262 | 16.68 | 121.1K | 18,889 | — | ↗ |
| 2022-10-14 | Eizen Joshua M | Officer | A-Award | A | Stock Option (right to buy) | 92,000 | 0.00 | — | 92,000 | — | ↗ |
| 2022-08-04 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | P-Purchase | A | Common Stock | 100 | 7.99 | 799.00 | 3,773,517 | — | ↗ |
| 2022-08-03 | Shah Rajeev M. | Director | P-Purchase | A | Common Stock | 1,809 | 7.48 | 13.5K | 3,773,417 | — | ↗ |
| 2022-08-03 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | P-Purchase | A | Common Stock | 1,809 | 7.48 | 13.5K | 3,773,417 | — | ↗ |
| 2022-07-27 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | P-Purchase | A | Common Stock | 8,281 | 7.91 | 65.5K | 3,771,608 | — | ↗ |
| 2022-07-26 | Shah Rajeev M. | Director | P-Purchase | A | Common Stock | 8,281 | 7.91 | 65.5K | 3,771,608 | — | ↗ |
| 2022-07-26 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | P-Purchase | A | Common Stock | 14,938 | 7.71 | 115.2K | 3,763,327 | — | ↗ |
| 2022-06-21 | Shah Rajeev M. | Director | P-Purchase | A | Common Stock | 302 | 7.99 | 2.4K | 3,748,389 | — | ↗ |
| 2022-06-21 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | P-Purchase | A | Common Stock | 302 | 7.99 | 2.4K | 3,748,389 | — | ↗ |
| 2022-06-14 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | P-Purchase | A | Common Stock | 61,424 | 7.97 | 489.4K | 3,748,087 | — | ↗ |
| 2022-06-13 | Shah Rajeev M. | Director | P-Purchase | A | Common Stock | 20,000 | 7.90 | 158.0K | 3,686,663 | — | ↗ |
| 2022-06-13 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | P-Purchase | A | Common Stock | 20,000 | 7.90 | 158.0K | 3,686,663 | — | ↗ |
| 2022-06-06 | Aziz Kabeer | Director | J-Other | A | Common Stock | 26,511 | 15.00 | 397.7K | 413,156 | — | ↗ |
| 2022-06-06 | Adjuvant Capital Management, LLC | Director | J-Other | A | Common Stock | 26,511 | 15.00 | 397.7K | 413,156 | — | ↗ |
| 2022-05-12 | Zakrzewski Joseph S | Director | A-Award | A | Stock Option (right to buy) | 10,362 | 17.28 | 179.1K | 10,362 | — | ↗ |
| 2022-05-12 | Wong Stephanie | Director | A-Award | A | Stock Option (right to buy) | 10,362 | 0.00 | — | 10,362 | — | ↗ |
| 2022-05-12 | Spigelman Melvin K | Director | A-Award | A | Stock Option (right to buy) | 10,362 | 0.00 | — | 10,362 | — | ↗ |
| 2022-05-12 | Readnour Robin Shane | Director | A-Award | A | Stock Option (right to buy) | 20,724 | 0.00 | — | 20,724 | — | ↗ |
| 2022-05-12 | Nazak Michael Adrian | Officer | A-Award | A | Stock Option (right to buy) | 14,300 | 0.00 | — | 14,300 | — | ↗ |
| 2022-05-12 | Martin Patricia A. | Director | A-Award | A | Stock Option (right to buy) | 10,362 | 0.00 | — | 10,362 | — | ↗ |
| 2022-05-12 | Marks Gilbert Lynn | Director | A-Award | A | Stock Option (right to buy) | 10,362 | 0.00 | — | 10,362 | — | ↗ |
| 2022-05-12 | Krause Kevin Michael | Officer | A-Award | A | Stock Option (right to buy) | 66,000 | 0.00 | — | 66,000 | — | ↗ |
| 2022-05-12 | FitzPatrick Margaret M | Director | A-Award | A | Stock Option (right to buy) | 10,362 | 0.00 | — | 10,362 | — | ↗ |
| 2022-05-12 | Eckburg Paul | Officer | A-Award | A | Stock Option (right to buy) | 66,000 | 0.00 | — | 66,000 | — | ↗ |
| 2022-05-12 | Easom Eric | Officer | A-Award | A | Stock Option (right to buy) | 225,000 | 0.00 | — | 225,000 | — | ↗ |
| 2022-05-12 | Day Lucy | Officer | A-Award | A | Stock Option (right to buy) | 66,000 | 0.00 | — | 66,000 | — | ↗ |
| 2022-05-12 | Chanda Sanjay | Officer | A-Award | A | Stock Option (right to buy) | 66,000 | 0.00 | — | 66,000 | — | ↗ |
| 2022-05-12 | Aziz Kabeer | Director | A-Award | A | Stock Option (right to buy) | 20,724 | 0.00 | — | 20,724 | — | ↗ |
| 2022-05-05 | FitzPatrick Margaret M | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-03-29 | Zakrzewski Joseph S | Director | C-Conversion | D | Series A Convertible Preferred Stock | 98,199 | 0.00 | — | 0 | — | ↗ |
| 2022-03-29 | Shah Rajeev M. | Director | P-Purchase | A | Common Stock | 115,613 | 15.00 | 1.73M | 415,612 | — | ↗ |
| 2022-03-29 | Readnour Robin Shane | Director | P-Purchase | A | Common Stock | 82,618 | 15.00 | 1.24M | 487,592 | — | ↗ |
Executive team
Top executives
Shares Outstanding
27.40M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Eric Easom President, Chief Executive Officer and Board Chair | 603.8K | — | 164.1K | 275.5K | 332.1K | 7.5K | 1.38M | 31.79% | ↗ |
| 2 | 2025 | Josh Eizen Chief Legal Officer and Chief Operating Officer | 450.0K | — | 66.1K | 111.0K | 180.0K | — | 807.1K | 21.94% | ↗ |
| 3 | 2025 | Lucy Day Chief Financial Officer | 447.2K | — | 52.5K | 88.2K | 178.9K | 7.5K | 774.3K | 18.18% | ↗ |
| 4 | 2024 | Eric Easom President, Chief Executive Officer and Board Chair | 603.8K | — | 297.0K | 508.8K | 249.0K | 7.5K | 1.67M | 48.37% | ↗ |
| 5 | 2024 | Josh Eizen Chief Legal Officer and Chief Operating Officer | 435.4K | — | 280.0K | 211.3K | 130.6K | — | 1.06M | 46.47% | ↗ |
| 6 | 2024 | Paul Eckburg, M.D. Former Chief Medical Officer | 325.5K | — | 90.0K | 154.2K | — | 376.8K | 946.5K | 25.80% | ↗ |
| 7 | 2024 | Lucy Day Chief Financial Officer | 447.2K | — | 82.5K | 141.3K | 134.2K | 7.5K | 812.7K | 27.54% | ↗ |
| 8 | 2023 | Eric Easom President, Chief Executive Officer and Board Chair | 575.0K | — | — | 2.42M | 345.0K | — | 3.34M | 72.48% | ↗ |
| 9 | 2023 | Eric Easom President and Chief Executive Officer | 575.0K | — | — | 2.42M | 345.0K | — | 3.34M | 72.48% | ↗ |
| 10 | 2023 | Lucy Day Chief Financial Officer | 430.0K | — | — | 888.1K | 206.4K | — | 1.52M | 58.25% | ↗ |
| 11 | 2023 | Paul Eckburg, M.D. Former Chief Medical Officer | 465.0K | — | — | 765.6K | 223.2K | — | 1.45M | 52.66% | ↗ |
| 12 | 2023 | Paul Eckburg, M.D. Chief Medical Officer | 465.0K | — | — | 765.6K | 223.2K | — | 1.45M | 52.66% | ↗ |
| 13 | 2023 | Josh Eizen Chief Legal Officer and Chief Operating Officer | 410.0K | — | — | 541.1K | 196.8K | — | 1.15M | 47.14% | ↗ |
| 14 | 2022 | Eric Easom President, Chief Executive Officer and Director | 481.2K | — | — | 2.77M | 216.5K | — | 3.47M | 79.87% | ↗ |
| 15 | 2022 | Eric Easom President and Chief Executive Officer | 481.2K | — | — | 2.77M | 216.5K | — | 3.47M | 79.87% | ↗ |
| 16 | 2022 | Paul Eckburg, M.D. Chief Medical Officer | 427.4K | — | — | 811.9K | 153.9K | — | 1.39M | 58.28% | ↗ |
| 17 | 2022 | Joshua Eizen, J.D. Chief Legal Officer | 101.7K | — | — | 1.22M | 36.6K | — | 1.35M | 89.78% | ↗ |
| 18 | 2022 | Lucy Day Chief Financial Officer | 379.9K | — | — | 811.9K | 136.8K | — | 1.33M | 61.11% | ↗ |
| 19 | 2021 | Eric Easom President, Chief Executive Officer and Director | 377.3K | — | — | 1.19M | 151.0K | — | 1.72M | 69.27% | ↗ |
| 20 | 2021 | Paul Eckburg, M.D. Chief Medical Officer | 258.1K | — | — | 567.9K | 77.0K | — | 903.1K | 62.89% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Eric E. Easom | Co-Founder, Chief Executive Officer, President & Chairman of the Board | 943.3K | male |
| Lucy O. Day | CFO, & Principal Financial Officer | 633.6K | female |
| Josh Eizen | Chief Legal Officer, Chief Operating Officer & Corporate Secretary | 630.0K | male |
| Joseph S. Zakrzewski | Co-Founder & Independent Director | 51.5K | male |
| Sanjay Chanda | Chief Development Officer | — | — |
| Sarah Williams | Vice President of Controller & Principal Accounting Officer | — | female |
| Vince Hernandez | Senior Vice President of Research & Head of Chemistry | — | male |
| Michael R. K. Alley | Co-Founder, Senior Vice President of Research Fellow & Head of Biology | — | — |
| George Harrison Talbot FACP | Co-Founder & Senior Clinical Advisor | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ANTX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
